Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-10-05)
CHF 7.80-3.94%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-39.8%1Y
60.8%3Y
290%5Y

Performance

56.4%1Y
64.9%3Y
73.6%5Y

Volatility

Market cap

188 M

Market cap (USD)

Daily traded volume (Shares)

77,016

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.25
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.75
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Interparfums
Interparfums Interparfums Valor: 86977
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.28%EUR 30.10
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.34%SEK 89.65
Estee Lauder Companies Inc
Estee Lauder Companies Inc Estee Lauder Companies Inc Valor: 99350
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.45%USD 93.30
Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.44%USD 87.23
Illumina Inc
Illumina Inc Illumina Inc Valor: 1111080
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.56%USD 293.69
Bausch Health Companies Inc
Bausch Health Companies Inc Bausch Health Companies Inc Valor: 42260834
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.74%USD 5.91
IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.05%USD 266.09
Medtronic PLC
Medtronic PLC Medtronic PLC Valor: 25187155
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.84%USD 87.97
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 76.43
BioVersys AG
BioVersys AG BioVersys AG Valor: 21036264
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.37%CHF 26.90